Radiopharm Theranostics Limited (RADX) 10-Year Financial Performance & Capital Metrics

RADX • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsSolid Tumor Oncology

AboutRadiopharm Theranostics Limited engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical needs. It develops RAD 204, a programmed death-ligand 1 (PD-L1) for the treatment of non-small cell lung cancer (NSCLC); RAD 202, a human epidermal growth factor receptor 2 (HER2) to treat breast cancer and other solid tumors; and RAD 301, a diagnostic radiopharmaceutical targeting avß6 integrin in pancreatic ductal adenocarcinoma patients. The company also develops RAD 302, an avß6-integrin targeting agent for the treatment of multiple cancer types; RAD 101 and RAD 102 for brain metastases; RAD 402 to treat advanced prostate cancer; and RV01 for multiple solid tumors. It has strategic agreement with Lantheus Holdings, Inc. to advance the clinical development of radiopharmaceuticals. The company was incorporated in 2021 and is based in Carlton, Australia.Show more

Revenue $4M +1114.3%
EBITDA -$38M -13.9%
Net Income -$38M +20.0%
EPS (Diluted) -5.28 +85.3%
Gross Margin 1.08% -98.9%
EBITDA Margin -1050.43% +90.6%
Operating Margin -1050.63% +91.4%
Net Margin -1055.27% +93.4%
ROE -109.2% +17.0%
ROIC -254.12% -97.3%
Debt/Equity -
Interest Coverage -584.59 -926.3%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Trading at only 0.8x book value

✗Weaknesses

✗Negative free cash flow
✗Shares diluted 100.0% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y643.76%

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-

EPS CAGR

10Y-

5Y-

3Y-

TTM-

ROCE

10Y Avg-50.08%

5Y Avg-50.08%

3Y Avg-57.97%

Latest-60.59%

Peer Comparison

Solid Tumor Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
TLXTelix Pharmaceuticals Limited	2.49B	7.43	53.07	55.85%	3.98%	15.63%	0.36%	1.02
EXELExelixis, Inc.	12.18B	45.44	25.82	18.49%	29.63%	31.37%	5.2%	0.09
BBOTBridgeBio Oncology Therapeutics Inc.	919.87M	11.50	25			-25.73%
INBXInhibrx Biosciences, Inc.	1.04B	71.80	0.62	-88.89%	-110.78%	-421.09%		0.06
NUVBNuvation Bio Inc.	2.1B	6.14	-2.91		-8.13%	-66.74%		0.02
RLAYRelay Therapeutics, Inc.	1.32B	7.63	-3.23	-60.83%	-26.71%	-48.97%		0.06
ORICORIC Pharmaceuticals, Inc.	1.12B	11.52	-6.30			-33.24%		0.01
ZLABZai Lab Limited	2.09B	18.82	-7.24	49.59%	-46.83%	-27.21%		0.18

Profit & Loss

	Jun 2022	Jun 2023	Jun 2024	Jun 2025
Sales/Revenue+	8.83K	292.36K	299.23K	3.63M
Revenue Growth %	-	32.11%	0.02%	11.14%
Cost of Goods Sold+	0	0	0	3.59M
COGS % of Revenue	-	-	-	0.99%
Gross Profit+	8.83K	292.36K	299.23K	39.28K
Gross Margin %	1%	1%	1%	0.01%
Gross Profit Growth %	-	32.11%	0.02%	-0.87%
Operating Expenses+	19.93M	34.8M	36.92M	38.21M
OpEx % of Revenue	2256.28%	119.03%	123.38%	10.52%
Selling, General & Admin	10.85M	13.02M	15.22M	16.53M
SG&A % of Revenue	1228.39%	44.54%	50.86%	4.55%
Research & Development	4.12M	13.8M	17.56M	27.52M
R&D % of Revenue	467.08%	47.2%	58.68%	7.57%
Other Operating Expenses	4.95M	7.98M	4.14M	-5.83M
Operating Income+	-19.92M	-34.51M	-36.62M	-38.17M
Operating Margin %	-2255.28%	-118.03%	-122.38%	-10.51%
Operating Income Growth %	-	-0.73%	-0.06%	-0.04%
EBITDA+	-16.93M	-31.21M	-33.49M	-38.17M
EBITDA Margin %	-1917.66%	-106.76%	-111.94%	-10.5%
EBITDA Growth %	-	-0.84%	-0.07%	-0.14%
D&A (Non-Cash Add-back)	2.98M	3.3M	3.13M	7.33K
EBIT	-20.94M	-34.49M	-47.21M	-38.17M
Net Interest Income+	-9.35M	58.94K	-592.4K	333.11K
Interest Income	0	145.03K	50.48K	888.2K
Interest Expense	9.35M	86.09K	642.89K	65.3K
Other Income/Expense	-10.38M	-65.1K	-11.23M	-65.3K
Pretax Income+	-30.29M	-34.57M	-47.85M	-38.24M
Pretax Margin %	-3430.48%	-118.26%	-159.92%	-10.52%
Income Tax+	44.4K	38.01K	96.36K	103.29K
Effective Tax Rate %	1%	1%	1%	1%
Net Income+	-30.34M	-34.61M	-47.95M	-38.34M
Net Margin %	-3435.51%	-118.39%	-160.24%	-10.55%
Net Income Growth %	-	-0.14%	-0.39%	0.2%
Net Income (Continuing)	-30.34M	-34.61M	-47.95M	-38.34M
Discontinued Operations	0	0	0	0
Minority Interest	0	1.19M	-769.28K	-1.92M
EPS (Diluted)+	-29.76	-33.00	-36.00	-5.28
EPS Growth %	-	-0.11%	-0.09%	0.85%
EPS (Basic)	-29.76	-33.00	-36.00	-5.28
Diluted Shares Outstanding	1.02M	1.02M	1.29M	6.94M
Basic Shares Outstanding	1.02M	1.02M	1.29M	6.94M
Dividend Payout Ratio	-	-	-	-

Balance Sheet

	Jun 2022	Jun 2023	Jun 2024	Jun 2025
Total Current Assets+	27.26M	16.3M	22.85M	39.85M
Cash & Short-Term Investments	26.98M	11.7M	18.58M	29.12M
Cash Only	26.98M	11.7M	18.58M	29.12M
Short-Term Investments	0	0	0	0
Accounts Receivable	56.48K	4.47M	987.41K	10.4M
Days Sales Outstanding	2.33K	5.58K	1.2K	1.04K
Inventory	0	0	0	0
Days Inventory Outstanding	-	-	-	-
Other Current Assets	228.82K	133.13K	3.29M	337.09K
Total Non-Current Assets+	56.12M	58.65M	49.19M	46.63M
Property, Plant & Equipment	1.58K	68.33K	60.8K	53.47K
Fixed Asset Turnover	5.60x	4.28x	4.92x	67.96x
Goodwill	0	0	0	0
Intangible Assets	56.08M	58.54M	49.09M	46.57M
Long-Term Investments	0	0	40K	0
Other Non-Current Assets	40K	40K	0	0
Total Assets+	83.38M	74.95M	72.04M	86.48M
Asset Turnover	0.00x	0.00x	0.00x	0.04x
Asset Growth %	-	-0.1%	-0.04%	0.2%
Total Current Liabilities+	7.88M	13.23M	17.58M	14.93M
Accounts Payable	1.19M	2.96M	6.43M	6.35M
Days Payables Outstanding	-	-	-	644.6
Short-Term Debt	0	0	0	0
Deferred Revenue (Current)	0	0	0	1000K
Other Current Liabilities	5.73M	8.11M	6.72M	3.87M
Current Ratio	3.46x	1.23x	1.30x	2.67x
Quick Ratio	3.46x	1.23x	1.30x	2.67x
Cash Conversion Cycle	-	-	-	-
Total Non-Current Liabilities+	12.54M	16.14M	27.11M	28.68M
Long-Term Debt	0	0	0	0
Capital Lease Obligations	0	0	0	0
Deferred Tax Liabilities	0	0	0	0
Other Non-Current Liabilities	12.54M	16.14M	27.11M	28.68M
Total Liabilities	20.42M	29.37M	44.68M	43.61M
Total Debt+	0	0	0	0
Net Debt	-26.98M	-11.7M	-18.58M	-29.12M
Debt / Equity	-	-	-	-
Debt / EBITDA	-	-	-	-
Net Debt / EBITDA	-	-	-	-
Interest Coverage	-2.13x	-400.83x	-56.96x	-584.59x
Total Equity+	62.96M	45.58M	27.35M	42.87M
Equity Growth %	-	-0.28%	-0.4%	0.57%
Book Value per Share	61.76	44.71	21.23	6.18
Total Shareholders' Equity	62.96M	44.38M	28.12M	44.79M
Common Stock	86.76M	97.23M	100.68M	176.56M
Retained Earnings	-30.82M	-65.35M	-111.34M	-145.73M
Treasury Stock	0	0	0	0
Accumulated OCI	7.03M	10.36M	37.93M	13.12M
Minority Interest	0	1.19M	-769.28K	-1.92M

Cash Flow

	Jun 2022	Jun 2023	Jun 2024	Jun 2025
Cash from Operations+	-9.92M	-23.2M	-22.98M	-36.65M
Operating CF Margin %	-1122.82%	-79.36%	-76.78%	-10.09%
Operating CF Growth %	-	-1.34%	0.01%	-0.59%
Net Income	-30.34M	-34.61M	-47.95M	0
Depreciation & Amortization	0	0	0	0
Stock-Based Compensation	0	0	0	0
Deferred Taxes	0	0	0	0
Other Non-Cash Items	20.42M	11.41M	24.97M	-36.65M
Working Capital Changes	0	0	0	0
Change in Receivables	0	0	0	0
Change in Inventory	0	0	0	0
Change in Payables	0	0	0	0
Cash from Investing+	-28.37M	-1.53M	-320K	1.77M
Capital Expenditures	-2.75K	-45.31K	0	0
CapEx % of Revenue	0.31%	0.15%	-	-
Acquisitions	-	-	-	-
Investments	-	-	-	-
Other Investing	-28.37M	-1.49M	-320K	1.77M
Cash from Financing+	65.11M	9.22M	30.2M	45.43M
Debt Issued (Net)	-	-	-	-
Equity Issued (Net)	-	-	-	-
Dividends Paid	0	0	0	0
Share Repurchases	-	-	-	-
Other Financing	0	0	-117K	-6.65M
Net Change in Cash	-	-	-	-
Free Cash Flow+	-38.25M	-24.73M	-22.98M	-36.65M
FCF Margin %	-4331.82%	-84.6%	-76.78%	-10.09%
FCF Growth %	-	0.35%	0.07%	-0.59%
FCF per Share	-37.52	-24.26	-17.84	-5.28
FCF Conversion (FCF/Net Income)	0.33x	0.67x	0.48x	0.96x
Interest Paid	0	0	0	0
Taxes Paid	0	0	0	0

Key Ratios

Metric	2021	2022	2023	2024
Return on Equity (ROE)	-48.19%	-63.77%	-131.49%	-109.2%
Return on Invested Capital (ROIC)	-41.51%	-74.09%	-128.77%	-254.12%
Gross Margin	100%	100%	100%	1.08%
Net Margin	-343550.89%	-11838.59%	-16024.28%	-1055.27%
Interest Coverage	-2.13x	-400.83x	-56.96x	-584.59x
FCF Conversion	0.33x	0.67x	0.48x	0.96x
Revenue Growth	-	3210.6%	2.35%	1114.27%

Revenue by Geography

	2024
UNITED STATES	3.63M
UNITED STATES Growth	-

Frequently Asked Questions

Growth & Financials

Radiopharm Theranostics Limited (RADX) reported $3.6M in revenue for fiscal year 2024. This represents a 41044% increase from $0.0M in 2021.

Radiopharm Theranostics Limited (RADX) grew revenue by 1114.3% over the past year. This is strong growth.

Radiopharm Theranostics Limited (RADX) reported a net loss of $38.3M for fiscal year 2024.

Dividend & Returns

Radiopharm Theranostics Limited (RADX) has a return on equity (ROE) of -109.2%. Negative ROE indicates the company is unprofitable.

Radiopharm Theranostics Limited (RADX) had negative free cash flow of $36.6M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener